Calithera Biosciences, Inc.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company…
Biotechnology
US, South San Francisco [HQ]
Ratios
11 Records · Starting from 2012Margins, Growth Rates In %
| Ratio | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||||
| Gross Margin | - - | - - | - - | - - | - - | 100.00 | 100.00 | - - | - - | 85.29 | - - | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Operating Margin | - - | - - | - - | - - | - - | -114.37 | -257.40 | - - | - - | -1,183.93 | - - | |
|
EPS Growth
|
- - | -55.17 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| EPS USD | -2,021.00 | -3,136.00 | -9,334.00 | -3,618.00 | -3,901.00 | -1,689.00 | -2,812.00 | -3,650.00 | -2,573.00 | -4,477.00 | -794.00 | |
| Return on Assets (ROA) | -260.62 | -35.52 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Return on Equity (ROE) | 93.05 | 59.47 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Return on Invested Capital (ROIC) | 93.05 | 59.47 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Solvency | ||||||||||||
| Equity Ratio | -200 | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Assets | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/Equity | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt/EBITDA | 45.78 | 279.60 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Debt/Capitalization
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Long-Term Debt/Capitalization | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Interest Debt per Share USD | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Debt Growth | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Liquidity | ||||||||||||
| Current Ratio | 249.94 | 2,542.34 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Quick Ratio | 249.94 | 2,542.34 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Cash Ratio | 242.57 | 2,516.37 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Operating Cash Flow Ratio | -700 | -800 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Turnover | ||||||||||||
| Inventory Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Receivables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Payables Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Asset Turnover
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Fixed Turnover | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Coverage | ||||||||||||
| Interest Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Asset Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Cash Flow Coverage (CFGR) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| EBITDA Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Dividend Coverage | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Time Interest Earned (TIE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Market Prospects | ||||||||||||
| Dividend Yield | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Earnings Yield | -10.74 | -16.66 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Price/Earnings (P/E)
|
-9.3143 | -6.0016 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Price/Earnings Growth (PEG) | - - | -10.88 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Price/Book (P/B)
|
-866.66 | -356.90 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Price/Tangible Book (P/TB) | -866.66 | -356.90 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Price/Sales (P/S) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Price/Cash Flow (P/CF)
|
-1,062.68 | -627.53 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Price/Free CF (P/FCF) | -1,055.28 | -618.96 | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Price/Operating CF (P/OCF) | -1,062.68 | -627.53 | - - | - - | - - | - - | - - | - - | - - | - - | - - |